IP Verse

Alexion Pharmaceuticals competitive analysis

Latest oppositions filed by Alexion Pharmaceuticals

Explore patent oppositions filed by Alexion Pharmaceuticals against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 3, 2026
Patent NumberTitleApplicantOpposition Date
EP2708559
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 31, 2018
EP2708558
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHADec 21, 2018
EP2552955
Antibodies With Modified Affinity To Fcrn That Promote Antigen ClearanceCHUGAI SEIYAKU KABUSHIKI KAISHAFeb 2, 2018
EP2006381
Method For Control Of Blood Kinetics Of AntibodyCHUGAI SEIYAKU KABUSHIKI KAISHANov 1, 2016
EP2275443
Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules RepeatedlyCHUGAI SEIYAKU KABUSHIKI KAISHASep 2, 2016

Latest patents of Alexion Pharmaceuticals opposed by its competitors

Explore Alexion Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 3, 2026
Patent NumberPublication DateTitleTotal Oppositions
EP3167888
May 1, 2024Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement3
EP2894165
Jan 4, 2023Methods And Compositions For Treating Complement-Associated Disorders2
EP2978451
Nov 27, 2019Compositions And Methods For Increasing The Serum Half-Life Of A Therapeutic Agent Targeting Complement C52
EP3207132
Jul 31, 2019Methods Of Shifting An Isoelectric Profile Of A Protein Product And Uses Thereof2
EP2359834
Nov 9, 2016Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement2
EP1988882
Dec 17, 2014Prolongation Of Survival Of An Allograft By Inhibiting Complement Activity2
EP1755674
Nov 19, 2014Prolongation Of Survival Of An Allograft By Inhibiting Complement Activity2

Latest PTAB cases involving Alexion Pharmaceuticals

Discover the latest PTAB cases involving Alexion Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 5, 2026
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Alexion Pharmaceuticals

IPR2023-01069Jun 16, 2023SAMSUNG BIOEPISALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-01069Jun 16, 2023SAMSUNG BIOEPIS UK LIMITEDALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-01070Jun 16, 2023SAMSUNG BIOEPISALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-01070Jun 16, 2023SAMSUNG BIOEPIS UK LIMITEDALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00998May 31, 2023SAMSUNG BIOEPISALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00998May 31, 2023SAMSUNG BIOEPIS UK LIMITEDALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00999May 31, 2023SAMSUNG BIOEPISALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00999May 31, 2023SAMSUNG BIOEPIS UK LIMITEDALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00933May 18, 2023SAMSUNG BIOEPISALEXION PHARMACEUTICALSTerminated-Settled
IPR2023-00933May 18, 2023SAMSUNG BIOEPIS UK LIMITEDALEXION PHARMACEUTICALSTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Alexion Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Sep 3, 2026
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ALEXION PHARMACEUTICALS515 - 8
CHUGAI SEIYAKU KABUSHIKI KAISHA3114 - 1
SAMSUNG BIOEPIS6518 -
SAMSUNG BIOEPIS UK LIMITED5118 -